Use of NEXIUM in pediatric patients is supported by extrapolation of results from adequate and well-controlled studies for adults and safety, pharmacokinetic, and pharmacodynamic studies performed in pediatric patients. Please see label for specific dosing and Indications. The safety and effectiveness of NEXIUM have not been established in patients <1 month of age.
A first-line treatment that’s FDA approved to treat your patients as young as 1 month
Multiple pediatric Indications from 1 month to 17 years old
- Short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis
- In infants 1 month to <1 year, NEXIUM is indicated for the short-term treatment (up to 6 weeks) of erosive esophagitis due to acid mediated gastroesophageal reflux disease (GERD)
- Short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in children 1 year and older
The safety and effectiveness of NEXIUM for patients younger than 1 month has not been established.